This company has been marked as potentially delisted and may not be actively trading. G1 Therapeutics (GTHX) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock GTHX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Drug developer seeks $100M for new cancer treatmentDecember 20, 2024 | bizjournals.comPharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender OfferSeptember 18, 2024 | globenewswire.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Shares Purchased by Acadian Asset Management LLCSeptember 15, 2024 | marketbeat.com177,051 Shares in G1 Therapeutics, Inc. (NASDAQ:GTHX) Acquired by Panagora Asset Management Inc.September 4, 2024 | marketbeat.comG1 Therapeutics Inc.August 30, 2024 | barrons.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, OBDC, PETQ on Behalf of ShareholdersAugust 20, 2024 | stockhouse.comVanguard Group Inc. Raises Stock Holdings in G1 Therapeutics, Inc. (NASDAQ:GTHX)August 16, 2024 | marketbeat.comQ3 2024 EPS Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX) Raised by AnalystAugust 12, 2024 | marketbeat.comGTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc.August 9, 2024 | globenewswire.comHold Rating Affirmed Amid G1 Therapeutics’ Acquisition by PharmacosmosAugust 9, 2024 | markets.businessinsider.comIn $400M deal for Triangle firm, familiar name is largest shareholderAugust 9, 2024 | bizjournals.comNeedham Downgrades G1 Therapeutics (GTHX)August 9, 2024 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of ShareholdersAugust 9, 2024 | globenewswire.comG1 Therapeutics, Inc. to Post Q3 2025 Earnings of ($0.04) Per Share, Wedbush Forecasts (NASDAQ:GTHX)August 9, 2024 | marketbeat.comHC Wainwright Lowers G1 Therapeutics (NASDAQ:GTHX) to HoldAugust 9, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Forecasted to Earn FY2027 Earnings of $0.16 Per ShareAugust 8, 2024 | marketbeat.comG1 Therapeutics (NASDAQ:GTHX) Downgraded by WedbushAugust 8, 2024 | marketbeat.comG1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational HighlightsAugust 8, 2024 | globenewswire.comG1 Therapeutics Shares Hit 52-Week High on Deal to Be AcquiredAugust 7, 2024 | marketwatch.comGTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to ShareholdersAugust 7, 2024 | stockhouse.comRTP company taken private in $405 million dealAugust 7, 2024 | bizjournals.comG1 Therapeutics To Be Acquired By Pharmacosmos For $7.15/shr In CashAugust 7, 2024 | markets.businessinsider.comG1 Therapeutics Q2 2024 Earnings PreviewAugust 7, 2024 | msn.comRTP drugmaker G1 Therapeutics taken private in $405 million dealAugust 7, 2024 | bizjournals.comG1 Therapeutics surges on merger deal with PharmacosmosAugust 7, 2024 | msn.comG1 Therapeutics (NASDAQ:GTHX) Stock Rating Reaffirmed by Needham & Company LLCAugust 7, 2024 | marketbeat.comG1 Therapeutics Target of Unusually High Options Trading (NASDAQ:GTHX)August 7, 2024 | marketbeat.comShareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public ShareholdersAugust 7, 2024 | prnewswire.comWhy Is G1 Therapeutics (GTHX) Stock Up 66% Today?August 7, 2024 | investorplace.comPharmacosmos Group to Acquire G1 TherapeuticsAugust 7, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2024 | globenewswire.comG1 Therapeutics (GTHX) to Release Quarterly Earnings on ThursdayAugust 1, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Short Interest UpdateJuly 28, 2024 | marketbeat.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are retail investors with 56% stake, while 28% is held by institutionsJuly 26, 2024 | finance.yahoo.comG1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024July 25, 2024 | globenewswire.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Shares Bought by Acadian Asset Management LLCJuly 25, 2024 | marketbeat.comG1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025July 15, 2024 | investorplace.comBiotech Bombshell: G1 Therapeutics Stock Is Too Much of a GambleJuly 10, 2024 | investorplace.comBiotech Bombshell: G1 Therapeutics Stock Is Too Much of a GambleJuly 10, 2024 | investorplace.comJohn E. (Jack) Jr. Bailey Sells 7,662 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) StockJuly 9, 2024 | insidertrades.comG1 Therapeutics Added to the Russell 2000® and 3000® IndexesJuly 1, 2024 | globenewswire.comFY2024 Earnings Forecast for G1 Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:GTHX)June 27, 2024 | marketbeat.comNeedham & Company LLC Trims G1 Therapeutics (NASDAQ:GTHX) Target Price to $6.00June 25, 2024 | marketbeat.comWedbush Reaffirms Outperform Rating for G1 Therapeutics (NASDAQ:GTHX)June 24, 2024 | marketbeat.comStock Traders Purchase High Volume of Put Options on G1 Therapeutics (NASDAQ:GTHX)June 24, 2024 | marketbeat.comWhy Is G1 Therapeutics (GTHX) Stock Down 56% Today?June 24, 2024 | investorplace.comG1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)June 24, 2024 | globenewswire.comNeedham & Company LLC Reiterates "Buy" Rating for G1 Therapeutics (NASDAQ:GTHX)June 13, 2024 | marketbeat.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2024 | globenewswire.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Short Interest Up 26.9% in MayJune 1, 2024 | marketbeat.com Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address GTHX Media Mentions By Week GTHX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GTHX News Sentiment▼0.000.57▲Average Medical News Sentiment GTHX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GTHX Articles This Week▼01▲GTHX Articles Average Week Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EVO News Today OCUL News Today VERA News Today ETNB News Today BHVN News Today ANIP News Today MESO News Today EWTX News Today JANX News Today TVTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GTHX) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share G1 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
